Zobrazeno 1 - 10
of 116
pro vyhledávání: '"V. J. Marder"'
Publikováno v:
Journal of Thrombosis and Haemostasis. 1:760-765
Summary. While protamine sulfate reverses the anticoagulant effect of standard heparin, there currently is no effective antidote for low molecular weight heparin (LMWH)-induced bleeding. Recently, recombinant activated factor VII (rFVIIa) was approve
Publikováno v:
Journal of Biological Chemistry. 268:26618-26624
After fibrin polymerizes to form a clot, the transglutaminase Factor XIIIa cross-links the gamma and alpha chains to stabilize the clot. There has been conflicting evidence on whether the gamma chain isopeptide bonds occur between molecules that are
Publikováno v:
Annals of hematology. 82(11)
We report a patient with hemoglobin sickle cell-hemoglobin C disease who developed the clinical syndrome of thrombotic thrombocytopenic purpura (TTP) during admission for typical acute pain crisis. The potential for multiorgan involvement secondary t
Publikováno v:
Thrombosis and haemostasis. 86(3)
The direct fibrinolytic enzyme, plasmin, was compared with tissue plasminogen activator (TPA) in rabbit models of local thrombolysis and fibrinolytic hemorrhage. Plasmin was produced by solid-phase urokinase activation of plasminogen and purified on
Autor:
W, Zareba, G, Pancio, A J, Moss, V G, Kalaria, V J, Marder, H J, Weiss, L F, Watelet, C E, Sparks
Publikováno v:
Thrombosis and haemostasis. 86(3)
Diabetes is an established risk factor for reinfarction and cardiac death in postinfarction patients. Since the underlying mechanism of diabetes-related risk is not fully understood we aimed to evaluate the association between lipids, thrombogenic fa
Autor:
F. Bachmann, V. J. Marder
Publikováno v:
Handbook of Experimental Pharmacology ISBN: 9783642630293
In 1933, the observation was made that an extract of hemolytic streptococci lyses fibrin (Tillett and Garner 1933), and it took 16 years for a therapeutic preparation, streptococcal fibrinolysin (streptokinase), to be used clinically to dissolve fibr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5443ed1e56df5ffccbc1ed232ae2a3da
https://doi.org/10.1007/978-3-642-56637-0_7
https://doi.org/10.1007/978-3-642-56637-0_7
Autor:
V G, Kalaria, W, Zareba, A J, Moss, G, Pancio, V J, Marder, J H, Morrissey, H J, Weiss, C E, Sparks, H, Greenberg, E, Dwyer, R, Goldstein, L F, Watelet
Publikováno v:
The American journal of cardiology. 85(12)
Thrombosis contributes to recurrent coronary events in patients after acute myocardial infarction (AMI), but prognostic significance of thrombogenic factors by gender is unknown. This study aimed to determine gender-related differences in the prognos
Publikováno v:
Thrombosis and haemostasis. 83(3)
Tissue factor (TF) is a transmembrane glycoprotein that serves as an essential cofactor for plasma coagulation factor VII. TF procoagulant activity exhibits varying species specificity. In particular, guinea pig (GP) TF is unable to activate clotting
Publikováno v:
Thrombosis and haemostasis. 82(6)
Hemostasis is initiated by tissue factor (TF) exposed on cellular phospholipid (PL) membranes, leading to thrombin generation. The binding of thrombin to thrombomodulin (TM), activates the protein C pathway, resulting in the inactivation of factors V
Publikováno v:
Thrombosis and haemostasis. 82(6)
The ability to identify the products of thrombin and plasmin action on fibrinogen is important in patients with thrombotic and fibrinolytic disorders. New assays have been developed for "soluble fibrin" which represents soluble derivatives other than